Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A11QVV0
Mon, 07.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study Ladenburg, Germany, 7 November 2022 – Heidelberg Pharma AG (FSE: HPHA) announced today that its licensing partner Telix Pharmaceuticals Limited, Melbourne, Australia, (Telix) presented positive top-line data on its pivotal ZIRCON Phase III study with [ … ]
Technical analysis
To the publication
Mon, 07.11.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma’s Partner Telix Reports Positive Data on the Pivotal ZIRCON Study Ladenburg, Germany, 7 November 2022 – Heidelberg Pharma AG (FSE: HPHA) announced today that its licensing partner Telix Pharmaceuticals Limited, Melbourne, Australia, (Telix) presented positive top-line data on its pivotal ZIRCON Phase III study with [ … ]
Technical analysis
To the publication
Thu, 13.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022 First clinical trial with HDP-101 in multiple myeloma on track, third patient cohort started Significant progress achieved in partner projects and further ATAC® agreements signed with Chiome Bioscience and Takeda Rights issue with proceeds of approximately EUR 8 [ … ]
Technical analysis
To the publication
Thu, 13.10.2022       Heidelberg Pharma AG
DE000A11QVV0

Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2022 First clinical trial with HDP-101 in multiple myeloma on track, third patient cohort started Significant progress achieved in partner projects and further ATAC® agreements signed with Chiome Bioscience and Takeda Rights issue with proceeds of approximately EUR 8 [ … ]
Technical analysis
To the publication
Tue, 30.08.2022       Heidelberg Pharma AG
DE000A11QVV0

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. PRESS RELEASE Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure All allowable shares  [ … ]
Technical analysis
To the publication
Tue, 30.08.2022       Heidelberg Pharma AG
DE000A11QVV0

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. PRESS RELEASE Heidelberg Pharma AG Raises Approximately EUR 80 Million From Capital Measure All allowable shares  [ … ]
Technical analysis
To the publication
Fri, 12.08.2022       Heidelberg Pharma AG
DE000A11QVV0

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. PRESS RELEASE Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million Ladenburg, Germany, 12 August 20 [ … ]
Technical analysis
To the publication
Fri, 12.08.2022       Heidelberg Pharma AG
DE000A11QVV0

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT. PRESS RELEASE Heidelberg Pharma AG Launches Rights Issue of up to EUR 80 Million Ladenburg, Germany, 12 August 20 [ … ]
Technical analysis
To the publication
Tue, 12.07.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2022 First clinical trial with HDP-101 in multiple myeloma on track, third cohort in preparation Signing of a strategic partnership with Huadong Medicine with an overall deal volume of up to one billion US dollars and an investment agreement of up to EUR 105 million; rights issue of up  [ … ]
Technical analysis
To the publication
Tue, 12.07.2022       Heidelberg Pharma AG
DE000A11QVV0

PRESS RELEASE Heidelberg Pharma Reports on First Half-Year 2022 First clinical trial with HDP-101 in multiple myeloma on track, third cohort in preparation Signing of a strategic partnership with Huadong Medicine with an overall deal volume of up to one billion US dollars and an investment agreement of up to EUR 105 million; rights issue of up  [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Thursday, 04.07.2024, Calendar Week 27, 186th day of the year, 180 days remaining until EoY.